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Although patients with Parkinson’s disease show impairments in cognitive performance even at the early stage of the disease,
the synaptic mechanisms underlying cognitive impairment in this pathology are unknown. Hippocampal long-term potentiation
represents the major experimental model for the synaptic changes underlying learning and memory and is controlled by
endogenous dopamine. We found that hippocampal long-term potentiation is altered in both a neurotoxic and transgenic
model of Parkinson’s disease and this plastic alteration is associated with an impaired dopaminergic transmission and a
decrease of NR2A/NR2B subunit ratio in synaptic N-methyl-D-aspartic acid receptors. Deficits in hippocampal-dependent learn-
ing were also found in hemiparkinsonian and mutant animals. Interestingly, the dopamine precursor L-DOPA was able to restore
hippocampal synaptic potentiation via D1/D5 receptors and to ameliorate the cognitive deficit in parkinsonian animals sug-
gesting that dopamine-dependent impairment of hippocampal long-term potentiation may contribute to cognitive deficits in
patients with Parkinson’s disease.
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Abbreviations: L-DOPA = L-3,4-dihydroxyphenylalanine; DOPAC = 3,4-dihydroxyphenylacetic acid; EPSP = excitatory postsynaptic
potential; 6-OHDA = 6-hydroxydopamine; LTP = long-term potentiation; NMDA = N-methyl-D-aspartic acid
Introduction
Parkinson’s disease causes impairments in cognitive performance
resembling those seen in frontal lobe patients (Robbins and
Arnsten, 2009), and progression of these deficits can lead to
dementia (Cools et al., 2001; Goetz et al., 2008). While
the motor abnormalities in Parkinson’s disease result from nigros-
triatal dopamine depletion, memory dysfunctions are induced
by degeneration of the dopaminergic mesocorticolimbic projec-
tions originating from the ventral tegmental area (Calabresi
et al., 2006).
The hippocampus is implicated in memory deficits observed in
Parkinson’s disease (Shohamy et al., 2009) since both structural
and functional abnormalities of this structure have been observed
in patients suffering from sporadic (Summerfield et al., 2005;
Joelving et al., 2006) and genetic forms of the disease (Helton
et al., 2008). In addition, hippocampal abnormalities positively
correlate with memory deficits (Bruck et al., 2004; Nagano-Saito
et al., 2005; Bouchard et al., 2008; Ibarretxe-Bilbao et al., 2008;
Jokinen et al., 2009) and behavioural alterations (Ibarretxe-Bilbao
et al., 2008).
The hippocampus is essential for encoding spatial and episodic
memories (Ryan et al., 2010), and for novelty detection (Jenkins
et al., 2004). Novelty detection involves the comparison of an
existing memory with new sensory information. Indeed, CA1 pyr-
amidal cells also receive direct sensory inputs from the cortex
(Lisman and Otmakhova, 2001). The dopaminergic system is a
strong candidate for modulating novelty acquisition and synaptic
plasticity in the hippocampal CA1 area. The ventral tegmental
area, the major brain source of dopaminergic inputs to the
limbic system and hippocampus, is part of a functional loop
detecting novelty (Lisman and Grace, 2005).
Hippocampal long-term potentiation (LTP) gates behaviourally
relevant information into long-term memory (Lisman and Grace,
2005). Dopamine is critically involved in this process since novel
stimuli trigger burst firing in ventral tegmental area cells (Horvitz
et al., 1997) whose projections reach the hippocampus (Gasbarri
et al., 1997) and make synapses with D1/D5 receptor-expressing
CA1 pyramidal cells (Ciliax et al., 2000).
Pharmacological modulation of D1/D5 receptors modifies LTP
recorded in the CA1 area (Frey et al., 1991; Huang and Kandel,
1995; Otmakhova and Lisman, 1996). This modulation is corre-
lated with memory tasks (Lemon and Manahan-Vaughan, 2006)
suggesting that loss of hippocampal dopamine innervation would
cause LTP impairment contributing to memory deficits in
Parkinson’s disease.
Intracellular accumulation of -synuclein is the pathological fea-
ture of Parkinson’s disease and monogenic forms of this disease
have been associated with mutations in the gene encoding for
this protein (Dawson et al., 2010). Although abnormalities in
hippocampal plasticity have been observed in -synuclein-related
models (Steidl et al., 2003; Gureviciene et al., 2009), the mech-
anisms underlying the alteration of hippocampal LTP and
hippocampal-related memory have never been analysed and com-
pared in a toxic and genetic model of Parkinson’s disease. To
address this issue, we investigated hippocampal dopamine trans-
mission and LTP in 6-hydroxydopamine (6-OHDA) hemilesioned
rats and -synuclein transgenic mice, expressing a truncated form
of human -synuclein (1–120; Tofaris et al., 2006).
Materials and methods
All the detailed methods and any associated references are available in
the online Supplementary material.
Rats with 6-hydroxydopamine-induced
lesion
Three-month-old 6-OHDA-lesioned rats (n = 81) were obtained as
previously reported (Picconi et al., 2003, 2008). Briefly, a group of
deeply anaesthetized (chloral hydrate, 400 mg/ml/kg) rats were
injected unilaterally with 6-OHDA (12 mg/4 ml of saline containing
0.1% ascorbic acid) into the medial forebrain bundle at a rate of
0.38 ml/min (anterioposterior = 4.4, lateral = + 1.2, ventrodorsal =
7.8). A group of rats were injected only with vehicle at the same
coordinates (sham-operated rats; n = 43). Fifteen days later, rats were
tested with 0.05 mg/kg subcutaneous apomorphine, and contralateral
turns to the lesion were counted for 40 min. The rats that showed
more than 200 contralateral turns were enrolled in the study.
Sham-operated animals did not show any turning behaviour. The se-
verity of the lesion was also quantified afterward by nigral tyrosine
hydroxylase immunohistochemistry. Experiments were performed 4–6
weeks after lesion.
Procedure for L-DOPA treatments
Subchronic treatment with L-3,4-dihydroxyphenylalanine (L-DOPA)
was performed by administration of 10 mg/kg L-DOPA plus 6.5 mg/
kg benserazide (intraperitoneal) twice a day for four consecutive days.
Mice were injected with 20 mg/kg L-DOPA plus 7.5 mg/kg bensera-
zide (intraperitoneal) once a day for four consecutive days. Both
L-DOPA and benserazide were dissolved in saline. Seven
sham-operated rats and 21 6-OHDA-lesioned rats were implanted
with indwelling cannulae six weeks after operation (Rossato et al.,
2009). Four groups of seven male Wistar rats were used: (i)
sham-operated, intraperitoneal saline-treated, plus saline injected in
the dorsal hippocampus (intrahippocampal); (ii) 6-OHDA-lesioned,
intraperitoneal saline-treated, plus intrahippocampal injected saline;
(iii) 6-OHDA-lesioned, subchronically treated with intraperitoneal
L-DOPA, plus intrahippocampal injected saline; and (iv) 6-OHDA-
lesioned, subchronically treated with intraperitoneal L-DOPA, plus
intrahippocampal injected SCH23390.
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Mice transgenic for truncated human
a-synuclein (1–120)
Male mice (3–4 months old) transgenic for truncated human -synuclein
(1–120; n = 23), produced on a C57BL/6S background (Harlan; Tofaris
et al., 2006), and control aged-matched C57BL/6S male wild-type mice
which is a strain of C57Bl/6 that lacks endogenous -synuclein (Harlan;
n = 18), were used in electrophysiological experiments, dopamine tissue
quantification, molecular analysis and for behavioural testing. In these
transgenic mice (-syn120), the expression of truncated human
-synuclein (1–120), driven by the tyrosine hydroxylase promoter on
a mouse -synuclein null background, leads to the formation of patho-
logical inclusions in the substantia nigra and olfactory bulb and to the
reduction in striatal dopamine levels. At the behavioural level, the trans-
genic mice show a progressive reduction in spontaneous locomotion.
Immunohistological procedure
In 6-OHDA rats, the severity of the lesion was confirmed afterward by
tyrosine hydroxylase immunohistochemistry. For each rat, tyrosine
hydroxylase-positive cells were counted at three different rostrocaudal
levels of the substantia nigra compacta at the level of the exiting of
the third nerve, 200mm rostral and 200mm caudal to this level. Cell
number was expressed as the mean number/section and the loss of
tyrosine hydroxylase-positive cells was analysed by two-way ANOVA,
followed by Tukey’s post hoc test.
Behavioural procedure
The protocol used for the hole-board test is a modified version of that
described by Kemp and Manahan-Vaughan (2008). Horizontal and ver-
tical movements were recorded in an automated apparatus (Imetronic).
The hole-board test was performed in two different experimental sec-
tions: (i) 6-OHDA-lesioned and sham-operated rats, -synuclein and
wild-type mice and (ii) hemiparkinsonian rats, -synuclein mice and
their relative controls, subchronically treated with L-DOPA. ANOVA
was used to analyse statistical differences between groups, and Tukey’s
Honestly Significant Difference test for post hoc comparisons.
Synaptosome preparation
and [3H]-dopamine analysis
Synaptosomes were prepared as previously described (Marti et al.,
2003). Briefly, hippocampus was homogenized in ice-cold 0.32M
sucrose buffer (pH 7.4), then centrifuged for 10 min at 2500gmax
(4C). The supernatant was centrifuged for 20 min at 9500gmax
(4C), and the synaptosomal pellet resuspended in oxygenated Krebs
solution. Synaptosomes were incubated with 50 nM [3H]-dopamine for
25 min, after which 1 ml aliquots of the suspension (0.35 mg protein)
were injected into nylon syringe filters maintained at 36.5C and
superfused (0.4 ml/min) with preoxygenated Krebs. Under these
superfusion conditions, spontaneous [3H]-dopamine efflux was essen-
tially unaffected by reuptake. Sample collection (every 3 min) was
initiated after a 20 min period of filter washout. Radioactivity in the
samples and in the filter (at the end of experiment) was measured by
liquid scintillation spectrophotometry.
Data, means  SEM of 6–8 determinations per group, were calcu-
lated as absolute content (pmol/mg protein), fractional release (i.e. trit-
ium efflux expressed as percentage of the tritium content in the filter
at the onset of the corresponding collection period) or net fractional
release, i.e. K + -evoked tritium overflow as percentage of the tritium
content in the filter at the onset of the corresponding collection period.
Statistical analysis was performed (Prism software) by one-way
ANOVA followed by the Newman–Keuls test for multiple comparisons.
When only two groups were compared, the Student t-test was used.
P-values5 0.05 were considered to be statistically significant.
Microdialysis
Microdialysis experiments were carried out in awake, freely moving
animals. Rats were anaesthetized, mounted in a stereotaxic frame
(David Kopf Instruments) and implanted with a guide cannula (stain-
less steel, shaft outer diameter of 0.38 mm, length 4 mm; Metalant
AB), in the hippocampus ipsilateral to the 6-OHDA-lesioned side (an-
terioposterior = 3.6; lateral = + 1.84). Experimental procedures were
performed as previously reported (Pascucci et al., 2007). Following the
onset of perfusion, rats were left undisturbed for 2 h and then dialys-
ates were collected at 20-min intervals for 3 h. Dialysate samples were
transferred to high-performance liquid chromatography systems for
biogenic amine detection. Both catecholamines were simultaneously
measured at the following conditions: the conditioning cell was set
at + 400 mV, electrode 1 at + 200 mV and electrode 2 at 250 mV;
the mobile phase was described previously (Westerink et al., 1998).
For 5-hydroxytryptamine detection, the conditioning cell was set at
+ 350 mV, electrode 1 at 150 mV and electrode 2 at + 200 mV; the
mobile phase was described previously (Gartside et al., 2003). A
Nova-Pack C18 column (3.9  150 mm; Waters) equipped with a
Sentry Guard Nova-Pack C18 pre-column (3.9  20 mm) maintained
at 32C was used. The limit of sensitivity of the assay was 0.1 pg. The
flow rate was 1.2 ml/min.
Tissue analysis
Tissue analysis was carried out as previously reported (Puglisi-Allegra
et al., 2000). Briefly, following decapitation, the brain was dissected
and put on an aluminium surface at 0C. The punches of hippocam-
pus were kept frozen and stored at 80C. On the day of analysis,
punches were weighed and homogenized in 0.05 M HClO4.
Tissue levels of dopamine, norepinephrine, homovanillic acid and
3,4-dihydroxyphenylacetic acid (DOPAC) were assessed simultan-
eously by a high-performance liquid chromatography system.
Subcellular fractionation and western
blot analysis
Purification of triton-insoluble postsynaptic fraction and western blot
analysis were performed as previously reported (Gardoni et al., 2006).
The following antibodies were used: polyclonal antibody anti-NR2B
and monoclonal antibody anti-NR2A from Zymed Laboratories, mono-
clonal antibody anti--Tubulin from Sigma-Aldrich.
Electrophysiological recordings
Mice and rats were anaesthetized with halothane before decapitation.
Under visual control, a stimulating electrode was inserted into the
Schaffer collateral fibres, and a recording electrode was inserted into
the CA1 region of the hippocampal slice (Sgobio et al., 2010). Field
excitatory postsynaptic potentials (fEPSPs) were filtered at 3 KHz, digi-
tized at 10 KHz and stored on a PC. For all of the experiments, data
are presented as mean  SEM (n is the number of slices). Off-line
analysis was performed using Clampfit (Molecular Devices) and
GraphPad Prism 3 (GraphPad Software) software. Two-way ANOVA
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was used for statistical analysis. The significance level was established
at P5 0.05.
For patch-clamp recordings, neurons of the CA1 region were visua-
lized using differential interference contrast (Nomarski) and infrared
microscopy (Olympus). Whole-cell voltage-clamp (holding potential,
60 mV) recordings were performed with borosilicate glass pipettes.
Postsynaptic currents (PSCs) of half-maximal amplitude were evoked
every 10 s; LTP was induced by a high-frequency stimulation protocol
consisting of three trains stimulating at same postsynaptic current
strength. Details are given in the Supplementary material.
Results
Features of dopamine denervation:
substantia nigra pars compacta versus
ventral tegmental area
6-OHDA injected into the rat medial forebrain bundle caused loss
of dopamine neurons located in both the substantia nigra pars
compacta and the ventral tegmental area (Fig. 1A). This procedure
was accompanied by loss of the efferent nigral projections to
the striatum and of the dopaminergic projections from the ventral
tegmental area (P5 0.001). However, as shown in Fig. 1A and B,
the dopaminergic loss was more evident in the substantia
nigra pars compacta than the ventral tegmental area (P50.001)
mimicking the pattern observed in Parkinson’s disease
(Damier et al., 1999). In fact, while some dopamine neurons
were spared in the ventral tegmental area, the dopamine
denervation was virtually complete in the substantia nigra pars
compacta.
Both spontaneous and stimulated
dopamine release is reduced in the
hippocampus of hemiparkinsonian rats
In order to assess whether loss of mesencephalic dopamine neu-
rons was associated with changes of dopamine release in the
hippocampus, hippocampal synaptosomes were obtained from
either dopamine-depleted or sham-operated rats. [3H]-dopamine
accumulation was slightly reduced (20%) in synaptosomes pre-
pared from the dopamine-depleted hippocampus of hemiparkin-
sonian rats with respect to the hippocampus of sham-operated
rats (0.67  0.022 and 0.84  0.027 pmol mg prot1min1,
respectively; Fig. 1C). Basal [3H]-dopamine efflux was reduced
by 22% in synaptosomes prepared from the dopamine-depleted
hippocampus (4.0  0.2%) compared with controls (6.19  0.2%;
Fig. 1D). Spontaneous tritium efflux was unaffected by omission
of Ca2 + from the perfusion medium both in 6-OHDA-treated and
sham-operated rats. A 2 min K + pulse evoked a tritium overflow
of 5.28  0.23%, which was largely (85%) Ca2 +-dependent
and therefore exocytotic in nature. K+ -evoked tritium overflow
was dramatically reduced (70%) in the dopamine-depleted
hippocampus. Also, in these conditions, K +-evoked tritium over-
flow was largely Ca2 + -dependent (Fig. 1E).
Biogenic amine outflow was evaluated by intracerebral micro-
dialysis in the hippocampus of dopamine-depleted (n = 8) or
sham-operated (n = 8) rats under basal conditions. The two
groups did not differ for either norepinephrine (sham-operated:
0.989  0.248 pg/20ml; dopamine-depleted: 1.221  0.286 pg/
20 ml) or 5-hydroxytryptamine (sham-operated: 3.920 
0.492 pg/20 ml; dopamine-depleted: 4.721  1.066 pg/20ml)
levels. Conversely, basal dopamine levels were significantly
reduced in dopamine-depleted (0.711  0.201 pg/20ml) compared
with sham-operated (2.758  0.773 pg/20 ml; *P50.05) rats
(Fig. 1F–H).
Hippocampal-dependent learning is
impaired in experimental parkinsonism:
reversal by L-DOPA
In order to explore whether endogenous hippocampal dopamine is
implicated in cognitive deficits observed in Parkinson’s disease, we
measured the ability of both 6-OHDA-depleted and sham-operated
rats (n = 10 for both groups) to recognize environmental spatial nov-
elty by utilizing an open-field hole-board (Fig. 2A–C). This test has
been demonstrated to involve the dorsal hippocampus and to be
dopamine-dependent (Lemon and Manahan-Vaughan, 2006). In
Session 1 (Fig. 2A and B), no significant differences in locomotor
(horizontal and vertical) activities were observed between groups
(P4 0.05). In the exposure of hole-board sessions (Fig. 2C),
two-way ANOVA revealed a significant interaction between
Group  Session main factors (P50.001). Post hoc analysis
showed a significant reduction of hole explorations in sham-operated
rats (P50.001) but not 6-OHDA-lesioned animals, indicating that
parkinsonian rats have a recognition deficit of novel context feature
(hole-board). Subchronic L-DOPA treatment administered (twice a
day for four consecutive days) 4 h before test restored normal per-
formance in lesioned rats (**P50.01; Fig. 2C).
To demonstrate that the behavioural effect induced by systemic
L-DOPA was really dependent on the activation of hippocampal
dopamine receptors, we injected the D1 receptor antagonist
SCH23390 (1.5mg/ml saline) in the hippocampus of dopamine-
depleted (n = 21) and sham-operated rats (n = 7). SCH23390 or
saline were injected (20 min before systemic L-DOPA administra-
tion) once a day for four consecutive days.
Intrahippocampal application of saline in sham-operated animals
did not produce significant alterations in recognition ability of new
context. Also, in hemiparkinsonian lesioned rats, cannula implant-
ation and handling procedure for injection did not alter the deficit
in recognition novelty and the capability of L-DOPA to restore
habituation process. Interestingly, intrahippocampal delivery of
SCH23390 fully prevented the L-DOPA-induced therapeutic
effect in parkinsonian animals (Fig. 2C). This observation supports
the critical involvement of hippocampal D1/D5 receptors in the
observed behavioural effects induced by L-DOPA. Moreover,
between-group post hoc comparisons revealed that sham-
operated rats explored the hole-board significantly more than the
other groups during first exposure (Fig. 2C). These results revealed
an effect of 6-OHDA on basal arousal activity of the animals.
L-DOPA treatment did not restore normal exploration activity
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Figure 1 Tyrosine hydroxylase-immunostaining and dopamine release in the hippocampus of sham-operated and hemiparkinsonian rats.
(A) Tyrosine hydroxylase (TH)-immunostaining in coronal section of midbrain of 6-OHDA-lesioned rat (scale bar = 1 mm). (B) 6-OHDA
treatment produces a selective cell death of dopamine (DA) neurons in both substantia nigra pars compacta (SNpc) and ventral tegmental
area (VTA) regions. Significant interaction Group  Region: F(1,18) = 37.6; ***P50.001. However, the dopaminergic denervation was
more evident in the substantia nigra than in the ventral tegmental area (***P50.001). (C–E) A synaptosomal preparation was obtained
from the dopamine-depleted hippocampus of hemiparkinsonian and sham-operated rats. [3H]-dopamine accumulation (C), efflux (D) and
K +-evoked overflow (E) were measured. K+ was applied for 2 min. Spontaneous [3H]-dopamine efflux and K +-evoked overflow were also
measured in Ca2 +-free conditions (D and E). Perfusion with Ca2 +-free Krebs solution started 9 min before the K + pulse and was
maintained until the end of experiments. Data, means  SEM of six determinations per group, are expressed in absolute values
(C), fractional release (FR) (D) or net fractional release (E: refer to ‘Materials and methods’ section for calculation details). (**P50.01
different from sham-operated rats, P5 0.01 different from synaptosomes in 1.2 mM Ca2 + Krebs.) (F–H) Biogenic amine outflow
measured in hippocampus of sham-operated and 6-OHDA rats by in vivo microdialysis. (F) Hippocampal release of DA is reduced in
6-OHDA-lesioned in comparison with sham-operated rats [dopamine-depleted 0.711  0.201 pg/20 ml versus sham-operated
2.758  0.773 pg/20 ml; F(1,14) = 6.571, *P50.05], while the two groups did not differ for either norepinephrine (NE) (G) or
5-hydroxytryptamine (5HT; H) hippocampal levels.
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suggesting that L-DOPA might fail to correct all the deficits caused
by dopamine denervation and that non-dopaminergic systems
might contribute to this deficit. Nonetheless, increasing brain dopa-
mine with L-DOPA allows the animals to habituate to the
hole-board in relation to their own level of arousal.
Hippocampal long-term potentiation is
reduced in hemiparkinsonian rats
CA1 pyramidal neurons were patch-clamped in slices from hemipar-
kinsonian (n = 9) and sham-operated (n = 6) rats. The current–volt-
age relationship revealed no differences in basal membrane
properties between neurons recorded in slices from sham-operated
and 6-OHDA-lesioned rats (Fig. 3A; P40.05). Postsynaptic currents
(PSCs) and extracellular field potential (field EPSP) recordings were
subsequently obtained from hippocampal slices taken from hemipar-
kinsonian and sham-operated rats (n = 20 and n = 8 for field EPSP
recordings, respectively). At the beginning of each experiment, an
input–output curve was obtained by stimulating the collateral
Schaffer fibres and recording from the CA1 region of the slice. The
comparison of the curves obtained from 6-OHDA and sham-
operated slices revealed no significant difference between groups
for both the postsynaptic current (Fig. 3B and C; n = 4 for each
group, P40.05) and for the field EPSP (n = 8 slices for each group).
Paired-pulse ratios of field EPSP slope, obtained at increasing
stimuli intervals (50–300 ms), revealed no differences between
6-OHDA and sham-operated slices (Fig. 3D; n = 7 slices for each
group, P40.05). For each experiment, after the recording of a
stable field EPSP for 20 min, a high-frequency stimulation protocol
was delivered to the slice. As presented in Fig. 3E, 60 min after
high-frequency stimulation protocol, a LTP occurred in the two
groups of animals. Interestingly, LTP recorded in 6-OHDA-
lesioned rats (n = 9 slices) was significantly reduced with respect
to that in sham-operated animals (n = 9 slices, P50.001). These
data were confirmed by voltage-clamp patch-clamp recordings in
6-OHDA-lesioned and sham-operated rats (Fig. 3F). The analysis
of the amplitude of postsynaptic current measured pre- and post-
the high-frequency stimulation showed a significant decrease of
LTP amplitude in 6-OHDA-lesioned rats compared with
sham-operated animals (Fig. 3F; n = 5 neurons for both groups;
P50.001). In sham-operated rats, LTP was significantly reduced
by bath application of the D1/D5 receptor antagonist SCH23390
(Supplementary Fig. 1A; sham in standard solution versus
SCH23390-treated rats, n = 9 and n = 11 slices, respectively;
P50.001). LTP in the CA1 contralateral to the lesioned side
was also significantly reduced by SCH23390 (Supplementary Fig.
1B; n = 4 slices for both groups; P50.001).
L-DOPA administration restores long-
term potentiation in the hippocampus of
hemiparkinsonian rats via D1/D5
dopamine receptors
We investigated the possibility to restore hippocampal LTP with
L-DOPA. Bath application of 30mM L-DOPA was able to rescue
LTP, as shown by recovery of field EPSP potentiation (Fig. 4A;
Figure 2 Hippocampal-related memory is altered in a
dopamine-dependent manner in hemiparkinsonian rats. (A)
Representative scheduling and session features of the open-field
hole-board test. (B) Horizontal (left) and vertical (right) activity
revealed no differences in locomotion between groups. (C) A
significant reduction of hole explorations in sham-operated
group but not in parkinsonian group indicated a recognition
deficit of novel context in 6-OHDA-lesioned animals whereas
subchronic L-DOPA treatment restored normal performance in
lesioned rats. Two-way ANOVA revealed a significant Group 
Session interaction [F(2,15) = 12.8; P5 0.001; Bonferroni post
hoc: Sham, first experiment versus second experiment
***P50.001; 6-OHDA + L-DOPA, first experiment versus
second experiment **P5 0.01]. Intrahippocampal (i.h.) appli-
cation of saline did not alter habituation observed in sham-
operated rats (***P5 0.001). Saline (intrahippocampal) also
failed to affect the deficit in habituation observed in 6-OHDA-
denervated animals (P40.05) and the restorative effect of
L-DOPA on habituation (**P50.01). Conversely, intrahippo-
campal administration of the D1 receptor antagonist SCH23390
fully prevented the restorative effect of systemic L-DOPA in
parkinsonian animals (P4 0.05, 1st exp versus 2nd exp). For
between-group comparisons, Sham-operated rats explore hole
significantly more than the other group during first exposure.
Bonferroni post hoc: Sham versus 6-OHDA ###P50.001; Sham
versus 6-OHDA + L-DOPA, #P5 0.05; Sham versus
6-OHDA + L-DOPA + SCH, ###P50.001. i.p. = intraperitoneal.
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n = 9 slices for each group; P50.001). Interestingly, L-DOPA did
not affect LTP amplitude in the hippocampus of sham-operated
rats (Supplementary Fig. 1A) or in the contralateral hippocampus
of 6-OHDA-lesioned rats (Supplementary Fig. 1B).
To test the hypothesis that L-DOPA effects were dependent on its
conversion to dopamine, we performed experiments in the presence
of the DOPA-decarboxylase inhibitor carbidopa. L-DOPA (30mM)
plus 100mM carbidopa were bath applied 20 min prior to the induc-
tion of LTP and throughout the experiment. In these conditions, LTP
was not different from that observed in untreated 6-OHDA slices
(Fig. 4A; n = 8 slices, P40.05).
To confirm the dopamine-dependence of hippocampal LTP,
we analysed LTP in slices obtained from 6-OHDA-lesioned animals
subchronically treated with L-DOPA. Similar to the acute effect of
L-DOPA, LTP was restored in L-DOPA treated animals (Fig. 4B; n = 6
for L-DOPA-treated rats and n = 9 for 6-OHDA rats; P50.001).
To investigate the dopamine receptor subtype involved in L-DOPA
action, we applied 30mM L-DOPA in the presence of the D1/D5
receptor blocker SCH23390 (10 mM). In this condition, L-DOPA
failed to restore LTP, suggesting that the action of L-DOPA was
due to its conversion to dopamine acting on D1/D5 receptors
(Fig. 4C; L-DOPA plus SCH23390, n = 5 versus control in the stand-
ard solution, n = 9 slices, P40.05). In slices obtained from
dopamine-denervated animals, SCH23390 failed to decrease the
LTP amplitude further (Supplementary Fig. 1C).
To confirm further the involvement of D1/D5 receptors, bath
application of the D1 dopamine receptor agonist SKF38393
mimicked the action of L-DOPA. In fact, bath application of
SKF38393 (10 mM) in 6-OHDA slices restored an LTP (Fig. 4D;
n = 6 slices; P50.001) similar to that measured in sham-operated
animals. Conversely, the D2 receptor agonist quinpirole (10mM)
was ineffective (Fig. 4D; n = 6 slices; P4 0.05).
Figure 3 Hippocampal-related LTP is altered in hemiparkinso-
nian rats. (A) Representative traces showing voltage membrane
changes to hyperpolarized and depolarized steps of current in-
jected into CA1 pyramidal neurons patched from slices of
sham-operated (left) and 6-OHDA lesioned rats (right). The
Figure 3 Continued
current–voltage relationship shows no difference in membrane
properties between neurons recorded from sham-operated and
6-OHDA lesioned rats. (B and C) Input–output plots obtained in
hippocampal slices from sham-operated and 6-OHDA-lesioned
rats by stimulating Schaffer fibres and recording EPSPs in neu-
rons by patch clamp measurements (B) or field EPSPs (fEPSP) by
extracellular field potential measurements (C) from the CA1
region. (D) Paired-pulse ratios (S2/S1) at different interstimulus
interval (50–300 ms) from slices cut from sham-operated and
6-OHDA rats. (E) Representative traces and time-course of field
EPSP slopes in slices from sham-operated and 6-OHDA rats.
Arrow indicates the time at which the high-frequency stimula-
tion (HFS) protocol is delivered. Note the reduced LTP in
6-OHDA group respect to the sham-operated group; [in
6-OHDA rats 123.2  7.0%, versus sham-operated animals
150.7  3.5%, n = 9 field EPSP for both, F(40,640) = 5.19;
***P50.001]. (F) Representative traces and time-course of
postsynaptic currents (PSCs) amplitude in slices from sham-
operated and 6-OHDA-lesioned rats. 6-OHDA rats show a
reduced LTP compared with the sham-operated group [Sham
179.1  14.0% versus 6-OHDA 92.3  4.5%, n = 5 neurons
for both groups, F(40,320) = 13.47; ***P50.001]. FV = fibre
volley.
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Figure 4 L-DOPA restores long-term potentiation in the hippocampus of 6-OHDA-lesioned rats by its conversion into DA activating D1
receptors. (A) Traces and time-course plots of field EPSP (fEPSP) recorded in the standard solution, in the presence of 30 mM L-DOPA and
in the presence of 30 mM L-DOPA plus 100mM carbidopa. Note the enhanced LTP in the presence of L-DOPA but not in the presence of L-
DOPA plus carbidopa; [161.3  5.0%, and 123.2  7.0% in the presence and the absence of L-DOPA, respectively, n = 9 field EPSPs for
each group, F(80,920) = 1.82; ***P50.001]. (B) Traces and time-courses of field EPSPs from slices of 6-OHDA lesioned rats and of
6-OHDA rats subchronically treated with L-DOPA [intraperitoneal; field EPSPs potentiation after systemic L-DOPA treatment,
166.8  9.5% versus field EPSPs potentiation in untreated hemiparkinsonian animals 123.2  7.0%, respectively; n = 6 for
L-DOPA-treated rats and n = 9 for 6-OHDA rats, F(40,520) = 5.97; ***P50.001]. (C) The traces and time-course plots show field EPSPs
recorded in the standard solution and in the presence of 30 mM L-DOPA plus the D1 DA receptor antagonist SCH23390 (SCH, 10 mM). (D)
Traces and time-course of field EPSPs recorded in the standard solution, in the presence of the D1 DA receptor agonist SKF38393 (SKF,
10 mM) [155.5  1.9%, n = 6 field EPSPs, F(80,720) = 5.93; ***P5 0.001] and in the presence of the D2 DA receptor agonist quinpirole
(10 mM; P4 0.05). HFS = high-frequency stimulation.
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Stimulated but not spontaneous
dopamine release is reduced in the
hippocampus of a-synuclein 1–120
transgenic mice
Taking advantage of the human -synuclein (1–120) genetic
model of Parkinson’s disease (Tofaris et al., 2006), we first
explored dopamine release in the hippocampus and analysed hip-
pocampal synaptic plasticity. [3H]-dopamine accumulation in hip-
pocampal synaptosomes did not differ between -syn120 and
wild-type (1.01  0.049 and 0.97  0.048 pmol mg prot1 min1,
respectively) mice (Fig. 5A). Likewise, basal [3H]-dopamine efflux
was similar (fractional release 6.9  0.3% and 6.6  0.3%,
respectively; Fig. 5B). Conversely, 10 mM K +-evoked tritium over-
flow was 20% lower in synaptosomes prepared from the hippocam-
pus of -syn120 mice (net fractional release 3.6  0.17%) than
wild-type mice (net fractional release 4.4  0.22%; Fig. 5C).
Moreover, we used high-performance liquid chromatography to
measure tissue level of endogenous dopamine content in the
hippocampus of -syn120 (n = 3) and wild-type (n = 3) mice. No
difference in dopamine content was found between -syn120 and
control mice (Fig. 5D; P40.05) whereas a decrease in homova-
nillic acid (a dopamine metabolite) was detected in -syn120 mice
(Fig. 5E; P50.01). Conversely, the levels of DOPAC (the
metabolite generated by monoamine oxidase) did not change
(data not shown). This evidence should be interpreted as a
decrease in dopamine turnover associated with a possible cat-
echol-O-methyltransferase (COMT) defect in the hippocampus
of this genetic Parkinson’s disease model. In addition, -syn120
mice presented a slight reduction in norepinephrine (Fig. 5F;
Figure 5 Dopamine release, hippocampal-related memory and
long-term potentiation are altered in transgenic -syn120 mice.
A synaptosomal preparation was obtained from the hippocam-
pus of wild-type and transgenic -syn120 mice. [3H]-dopamine
(DA) accumulation (A), efflux (B) and K+-evoked overflow (C)
were measured. K+ was applied for 2 min. Data, means  SEM
of six determinations per group, are expressed in absolute values
(A), fractional release (FR) (B) or net fractional release (C)
(**P50.01). (D–G) DA, homovanillic acid, norepinephrine and
5-hydroxytryptamine (5HT) tissue levels (ng/g wet weight) in
hippocampus of wild-type and transgenic -syn120 mice. The
Figure 5 Continued
two groups did not differ for hippocampal dopamine, DOPAC or
5-hydroxytryptamine levels, while norepinephrine [-syn120
342.7  14.8 ng/g versus wild-type 409.3  25.6 ng/g,
t(10) = 2.25; *P50.05] and homovanillic acid [-syn120
17.62  1.2 ng/g versus wild-type 26.52  2.4 ng/g,
t(10) = 3.24; **P50.01] tissue levels from the hippocampus of
-syn120 mice were significantly reduced. (H and I) Locomotor
activities of transgenic -syn120 mice were not altered
(P40.05). (J) Two-way ANOVA revealed a significant
Group  Session interaction in hole-board sessions
[F(1,8) = 6.08; P5 0.05]. Exposure of mice to hole-board ses-
sions showed a significant habituation in wild-type mice
(**P50.01) but not in -syn120 transgenic animals (P4 0.05).
(K) Input–output plots obtained in hippocampal slices from
wild-type mice and -syn120 mice by stimulating Schaffer fibres
and recording in the CA1 region. (L) Paired-pulse ratios (S2/S1)
at different interstimulus interval (50–300 ms) from slices cut
from wild-type and -syn120 mice. (M) Example traces of field
EPSPs from a slice of a wild-type mouse (left) and a -syn120
mouse (right). Time-course of field EPSP slopes showing a
reduced LTP in slices from -syn120 mice with respect to
wild-type mice; [-syn120 137.2  7.8% versus wild-type
169.2  7.5%, n = 10 field EPSPs, F(40,720) = 7.59;
***P50.001].
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P5 0.05), but no difference in 5-hydroxytryptamine levels
(Fig. 5G; P4 0.05) compared with control mice, which may
point to the role of others catecholaminergic neurotransmitters
in cognitive disturbances in these mice.
Hippocampal-dependent learning and
long-term potentiation are impaired in
a-synuclein 1–120 transgenic mice
Hole-board task in -syn120 transgenic mice (n = 5; Fig. 5H–J)
revealed a deficit in hippocampal-dependent learning similar to
that observed in 6-OHDA hemilesioned rats. Locomotor activities
of these animals (horizontal and vertical) were not altered in the
first session. However, two-way ANOVA revealed a significant
Group  Session interaction in hole-board sessions (P50.05).
In particular, post hoc comparison showed a significant habitu-
ation in hole exploration in wild-type (Fig. 5J; P5 0.01) but not
-syn120 transgenic mice. L-DOPA treatment partially restored the
hippocampal-dependent learning deficit in -syn120 transgenic
mice (data not shown).
Basic electrophysiological properties as well as short-term and
long-term synaptic plasticity were then studied in CA1 hippocam-
pal area. Field EPSPs were recorded in hippocampal slices either
from -syn120 transgenic (n = 10) or wild-type (n = 10) mice to
obtain input–output curves. No significant genotype differences
emerged from curves comparison (Fig. 5K; n = 6 slices for each
group, P40.05).
Paired-pulse ratios of field EPSP slope (interstimulus interval
50–300 ms) showed no difference between -syn120 and
wild-type slices (Fig. 5L; n = 6 slices for each group, P40.05).
After acquiring a stable field EPSP for 20 min, the high-frequency
stimulation protocol was delivered. Interestingly, the LTP obtained
in slices recorded from -syn120 mice was significantly reduced
(Fig. 5M; n = 10 slices) with respect to the LTP in wild-type mice
(Fig. 5M; n = 10 slices; P50.001).
L-DOPA restores long-term potentiation
in the hippocampus of a-synuclein
1–120 transgenic mice
In order to assess whether the LTP impairment in -syn120 trans-
genic mice could be related to an altered dopamine transmission, we
tested whether L-DOPA reversed this deficit acting on D1/D5 recep-
tors. Bath application of L-DOPA (30mM) restored LTP (Fig. 6A;
n = 7 slices; P50.001). This effect was reversed by SCH23390
(10 mM, Fig. 6A, n = 4). LTP was also restored in transgenic mice
systemically treated with L-DOPA for 4 days (Fig. 6B; n = 8 slices;
P50.001). SCH23390 failed to decrease the amplitude of LTP re-
corded from transgenic mice further (Supplementary Fig. 1D).
Altered distribution of NMDA receptor
subunits in 6-hydroxydopamine-
lesioned rats and in a-synuclein 1–120
transgenic mice
NR2 subunits of N-methyl-D-aspartic acid (NMDA) receptor play a
key role in hippocampal plasticity and LTP. To explore the possi-
bility that LTP impairment observed in 6-OHDA hemilesioned rats
and -syn120 transgenic mice also share common dysfunction of
glutamate synapse, levels of NR2A and NR2B NMDA receptor
Figure 6 L-DOPA restores long-term potentiation in the
hippocampus of -syn120 transgenic mice. (A) Traces and
time-course plots of field EPSP (fEPSP) recorded in the standard
solution and in the presence of 30 mM L-DOPA; L-DOPA bath
application restored LTP [180.4  2.5%, n = 7 field EPSPs,
F(40,480) = 4.17; ***P50.001] whereas it had no effect in
restoring LTP when coapplied with 10 mM SCH23390
(149.6  6.0%, n = 4). (B) Traces and time-courses of field
EPSPs recorded from slices of -syn120 mice subchronically
treated with L-DOPA (intraperitoneal); LTP was also restored in
transgenic mice that had been systemically treated with L-DOPA
for 4 days [204.3  6.7%, n = 8 field EPSPs, F(40,560) = 9.66;
***P50.001]. HFS = high-frequency stimulation.
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subunits were analysed in hippocampal purified Triton-insoluble
postsynaptic fractions (TIF) from 6-OHDA-lesioned (n = 5) and
sham-operated rats (n = 5; Fig. 7A). In 6-OHDA-lesioned animals,
the level of NR2A subunit in Triton-insoluble postsynaptic fractions
was normal. However, dopamine-denervated animals were char-
acterized by a significant increase in the NR2B immunostaining
( + 57.0  6.2%, P50.005 compared with sham-operated);
accordingly, the NR2A/NR2B ratio was significantly decreased
(29.4  7.6%, P50.05 compared with sham-operated) sug-
gesting the presence of a profound rearrangement of the
NMDA receptor composition in 6-OHDA-lesioned rats.
We also evaluated whether the LTP impairment in -syn120
transgenic mice (n = 5) was correlated with changes in NMDA
receptor composition in the postsynaptic compartment. Interest-
ingly, a decrease in NR2A (30.7  6.7%, P50.05 compared
with wild-type, n = 5) and a concomitant decrease in the NR2A/
NR2B ratio (35.2  4.9%, P50.05 compared with wild-type)
were detected in -syn120 transgenic mice compared with
wild-type mice (Fig. 7B). These findings demonstrate that,
although toxic and genetic models of Parkinson’s disease show
distinct neurochemical and molecular patterns, they can share
similar alterations in the NR2A/NR2B ratio, possibly leading to a
reduced hippocampal LTP.
Influence of NMDA receptor
subunits on hippocampal long-term
potentiation in sham-operated and
6-hydroxydopamine-lesioned rats
In order to investigate the role of NMDA receptor subunits on
CA1 hippocampal LTP recorded in sham-operated and 6-OHDA
denervated animals (n = 5 for each group), we analysed synaptic
plasticity in the presence of ifenprodil, an antagonist of NR2B
receptor subunit. Ifenprodil (1 mM) significantly reduced the LTP
observed in sham-operated animals (Fig. 8A; n = 5, P5 0.001),
while it did not affect the LTP amplitude in dopamine-denervated
rats (Fig. 8B; n = 4, P40.05). Previous studies have shown the
capability of cell-permeable TAT peptides fused to the C-terminal
domain of NMDA receptor subunits to reach and to disrupt
Figure 7 Altered distribution of NMDA receptor subunits in 6-OHDA-lesioned and in -syn120 transgenic animals. Hippocampal
Triton-insoluble fractions (TIF) from parkinsonian and control animals were analysed by western blot analysis with antibodies for NMDA
receptor NR2A and NR2B subunits. The same amount of protein was loaded per lane. Histograms show the quantification of western
blotting performed in hippocampal TIF from 6-OHDA and sham-operated rats (A) and from -syn120 transgenic and wild-type mice (WT)
(B); (*P5 0.05, **P50.005).
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Figure 8 Influence of NMDA receptor subunits on hippocampal LTP in sham-operated and 6-OHDA-lesioned rats. Traces and
time-course plots of field EPSP (fEPSP) recorded from sham-operated (A, C and E) and 6-OHDA-lesioned rats (B, D and F). The treatment
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NMDA/PSD-MAGUKs (PSD-95-like membrane associated guany-
late kinases) association both in in vitro and in vivo studies (Aarts
et al., 2002; Gardoni et al., 2006). Thus, we also analysed LTP in
the presence of the cell-permeable peptides TAT2A and TAT2B,
respectively, and selectively targeted NR2A and NR2B subunits of
NMDA receptor in both sham-operated and 6-OHDA denervated
rats. In these experiments, slices were incubated with either TAT2B
or TAT2A before (at least 2 h) and during the electrophysiological
recordings. The application of 300 nM TAT2B peptide significantly
decreased LTP in sham-operated animals (Fig. 8C; n = 3,
P5 0.001), as previously reported for CA1 hippocampal LTP in
control animals (Gardoni et al., 2009). However, this peptide, in
sharp difference with ifenprodil, fully restored LTP to control levels
in 6-OHDA denervated rats (Fig. 8D; n = 5, P5 0.001) suggesting
that the correct assembly of the NMDA receptor subunits, rather
than their pharmacological blockade, is necessary to restore
physiological plasticity. In line with this observation, we also
found that the TAT2A peptide significantly decreased CA1 LTP
in sham-operated animals (Fig. 8E; n = 8, P50.001) but not in
dopamine-denervated animals (Fig. 8F; n = 4, P4 0.05), confirm-
ing the molecular data and further supporting the hypothesis that
a correct balance between NR2A and NR2B is critically important
for LTP induction.
Discussion
In the present study, we have shown that CA1 hippocampal LTP is
reduced in both a neurotoxic and a genetic model of Parkinson’s
disease. This plastic alteration is associated with neurochemical
changes of dopamine transmission, deficits of hippocampal-related
memory tasks and abnormalities in the expression of hippocampal
NMDA receptor subunits. We achieved these results by analysing,
for the first time, the role of hippocampal synaptic plasticity in
both a toxic and a genetic model of Parkinson’s disease using
combined electrophysiological, behavioural, molecular and neuro-
chemical approaches. The 6-OHDA-induced lesion is still the most
widely used model for replicating a Parkinson’s disease-like loss of
nigral dopaminergic neurons and it is currently adopted for the
analysis of striatal synaptic plasticity and its link with motor symp-
toms. Surprisingly, this toxic model has been less utilized to inves-
tigate altered synaptic plasticity in other brain areas such as
hippocampal LTP and the correlated memory deficits. On the
other hand, the genetic model used in the present study expresses
truncated human -synuclein (1–120), leading to the formation of
pathological inclusions in the substantia nigra pars compacta and
olfactory bulb and to a reduction in striatal dopamine levels.
At the behavioural level, transgenic mice show a progressive re-
duction in spontaneous locomotion mimicking the pathological
and clinical features of Parkinson’s disease (Tofaris et al., 2006).
However, hippocampal dopamine transmission and plasticity and
their possible involvement in memory deficits have never been
deeply investigated in genetic models.
Two major findings suggest that the reduction of endogenous
hippocampal dopamine plays a major role in the decrease of LTP
in experimental parkinsonism. First, in the 6-OHDA denervated
hippocampus the release of dopamine during membrane depolar-
ization is significantly reduced in comparison with control animals.
Secondly, in both neurotoxic and genetic models of Parkinson’s
disease, the administration of L-DOPA, a dopamine precursor,
restores a physiological LTP. The effect of L-DOPA is blocked by
hippocampal administration of a DOPA-decarboxylase inhibitor
such as carbidopa, further supporting the idea that L-DOPA does
not exert its therapeutic action on hippocampal synaptic plasticity
per se but only after its conversion to dopamine.
In our 6-OHDA-induced lesioned model of Parkinson’s disease,
the dopaminergic loss was complete in substantia nigra pars com-
pacta while some dopamine neurons were spared in the ventral
tegmental area. This condition partially mimics Parkinson’s disease
where there is a more severe loss of dopamine cells in substantia
nigra pars compacta than in ventral tegmental area. However, a
significant cell loss in the ventral tegmental area has been
observed in Parkinson’s disease brains (Uhl et al., 1985; German
et al., 1989).
Interestingly, an impaired hippocampal LTP and an altered
hippocampal-dependent memory were also observed in a trans-
genic mouse model for -synuclein aggregation obtained by the
expression of human -syn120 under the control of the tyrosine
hydroxylase promoter (Tofaris et al., 2006). These findings do not
match with a previous observation in which no difference in
hippocampal LTP was reported in a transgenic mouse line carrying
the -synuclein A30P mutation (Steidl et al., 2003). These
data, however, were obtained in a mouse line showing normal
dopamine levels, dopamine receptor number and dopamine func-
tion, features that are importantly different from those of
the -syn120 model, where dopamine signalling was affected
(Tofaris et al., 2006; Garcia-Reitbock et al., 2010).
The absence of motor abnormalities observed in mutant mice in
our study is in line with a previous study showing that, in these
mice, spontaneous locomotor activity was altered at 18 but not at
6 months of age (Tofaris et al., 2006). Thus, at least in this genetic
model, deficits in hippocampal function seem to precede motor
symptoms.
Figure 8 Continued
with 1mM ifenprodil, a drug targeting the NR2B NMDA receptor subunit, reduces the CA1 LTP with respect to control in sham-operated
rats [134.7  13%, n = 5 field EPSPs, F(39,273) = 3.12; ***P50.001] (A) but not in 6-OHDA-lesioned animals (B). The treatment with
300 nM TAT2B, targeting NR2B assembly into functional NMDA receptors, reduces the CA1 LTP with respect to control in sham-operated
rats [117.7  2%, n = 3 field EPSPs, F(39,195) = 6.43; ***P50.001] (C) whereas LTP is restored in 6-OHDA animals [154.7  14.4%,
n = 5 field EPSPs, F(39,234) = 3.44; ***P5 0.001] (D). The treatment with 300 nM TAT2A, targeting NR2A NMDA receptor subunit,
slightly reduces the LTP with respect to control in sham-operated rats [142.4  8.2%, n = 4 field EPSPs, F(39,234) = 1.85; **P5 0.01]
(E) but it does not alter LTP in 6-OHDA animals (F). HFS = high-frequency stimulation.
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Unlike patients with Parkinson’s disease and 6-OHDA rats,
-syn120 mice do not show significant neuronal cell death
(Tofaris et al., 2006). Thus, impairment of dopamine transmission
in hippocampus (present study) and striatum (Tofaris et al., 2006)
cannot be attributed to dopamine cell loss but more likely to func-
tional changes of the release machinery caused by the early accu-
mulation of -syn120 in presynaptic terminals. Accordingly,
alterations in dopamine release associated with redistribution of
SNARE proteins have recently been described in the striatum of
these mice (Garcia-Reitbock et al., 2010).
The hippocampus represents a key structure for the formation
of spatial and episodic memories (Ryan et al., 2010) as well as for
the detection of novelty (Jenkins et al., 2004). This structure is
critically involved in the storage of information such as memory for
places (Muzzio et al., 2009). In line with this view, in the present
study we found that habituation to a novel environment is altered
in hemiparkinsonian animals bearing impaired hippocampal LTP,
and that these behavioural and biochemical deficits, as well as
abnormalities in synaptic plasticity, can be reversed by systemic
L-DOPA. Thus, our data provide a novel link among spatial
memory, hippocampal LTP and neurochemical changes underlying
Parkinson’s disease.
The ventral tegmental area/hippocampal dopaminergic loop
regulates the flux of information into long-term memory and
this system is believed to play an important role in information
acquisition and synaptic plasticity (Lisman and Grace, 2005). It has
been proposed that the CA1 neurons could detect mismatches
between predictions from the dentate gyrus–CA3 network and
sensory input from the cortex (Lisman and Otmakhova, 2001).
The behavioural function exerted by the CA1 hippocampal area
could be of critical importance since novelty detection involves the
comparison of an existing memory with new sensory information.
D1/D5 dopamine receptors play a major role in hippocampal
CA1 LTP and associative learning (Frey et al., 1991; Otmakhova
and Lisman, 1996; Sajikumar and Frey, 2004; Granado et al.,
2008; Ortiz et al., 2010). D1/D5 receptors are involved in
object configuration learning and are required for LTP induced
by exploration of empty space (Lemon and Manahan-Vaughan,
2006). In line with these data obtained in physiological conditions,
in the present study, we found that the therapeutic action of
L-DOPA on hippocampal LTP in parkinsonian animals could be
blocked by a D1/D5 receptor antagonist and mimicked by a
D1/D5 but not D2/D3 receptor agonist.
Our data allow the establishment of an intriguing association
between the roles of D1/D5 receptors in hippocampal synaptic
plasticity and cognitive dysfunction in Parkinson’s disease. In
fact, although both L-DOPA (acting on all the different types of
dopamine receptors after its conversion to dopamine) and D2
receptor agonists are widely used in patients with Parkinson’s dis-
ease to improve motor function, they cause different modulation
on neuropsychological functions (Robbins and Arnsten, 2009).
Several studies have suggested that NR2A- and NR2B-
containing receptors have different roles in the regulation of the
induction of LTP in the hippocampus. Enhanced expression of
NR2B seems to facilitate the induction of LTP (Tang et al.,
1999; Foster et al., 2010). It has been postulated that the NR2B
subunit plays a critical role for LTP, presumably by recruiting
relevant molecules important for LTP via its cytoplasmic tail
(Foster et al., 2010). In contrast, NR2A does not seem to be crit-
ical for the LTP and its cytoplasmic tail seems to carry inhibitory
factors for LTP (Foster et al., 2010). Accordingly, hippocampal LTP
is severely impaired by experimental approaches selectively target-
ing NR2B NMDA subunit, such as selective NR2B antagonists
(Bartlett et al., 2007), antisense knockdown of NR2B (Clayton
et al., 2002) and cell-permeable peptides reducing the NR2B
localization to synaptic sites (Gardoni et al., 2009). Conversely,
Liu et al. (2004) showed that NR2A but not NR2B subunits are
required for hippocampal LTP. Differences in the experimental
approaches used might possibly account for the obtained conflict-
ing results. However, an emerging concept derived from all these
studies is the requirement of a correct balance in the NR2A/NR2B
subunit composition at hippocampal synapses as a critical condi-
tion for LTP induction (Liu et al., 2004; Bartlett et al., 2007;
Bellone and Nicoll, 2007; Morishita et al., 2007; Gardoni et al.,
2009). In agreement with these studies, here we show that,
although a toxic and a genetic model of Parkinson’s disease
both show distinct neurochemical and molecular changes, they
can induce a significant decrease of NR2A/NR2B subunit ratio in
hippocampal synaptic NMDA receptors possibly leading to LTP
impairment and memory dysfunctions. These molecular findings
are also supported by our electrophysiological experiments show-
ing that, while the TAT2B peptide reduces LTP in sham-operated
animals showing a normal NR2A/NR2B ratio, in 6-OHDA dener-
vated rats it restores this form of synaptic plasticity to a control
level. These molecular and electrophysiological findings suggest
that changes in the NR2A/NR2B ratio at CA1 hippocampal syn-
apses might be a key factor to explain both plastic and cognitive
dysfunction in Parkinson’s disease.
In conclusion, the concomitant deficits in hippocampal LTP
observed in the present study together with the altered dopa-
mine-dependent basal ganglia synaptic plasticity reported in par-
kinsonian animals (Calabresi et al., 2007) and patients with
Parkinson’s disease (Calabresi et al., 2009; Prescott et al., 2009)
might represent the synaptic mechanisms underlying the complex
neuropsychological scenario associated with human Parkinson’s
disease.
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